Detection of nucleic acids from multiple types of human papillomaviruses

• US 8,026,066 B2
• Filed: 12/21/2009
• Issued: 09/27/2011
• Est. Priority Date: 12/08/2004
• Status: Active Grant

• Current Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Original Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Inventors: Norman, Sylvia A., Rao, Neeraj P., Hanna, William L., Bungo, Jennifer J.
• Primary Examiner(s): Babic; Christopher M.
• Application Number:
  US12/643,934
• Publication Number:
  US 20100105027A1
• Time in Patent Office: 645 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.

Claims

1. A combination of oligonucleotides for detecting human papillomavirus (HPV) target sequences in multiple HPV types, the combination of oligonucleotides comprising amplification oligomers for amplifying a region of an E6/E7 gene from HPV, wherein the amplification oligomers are a first amplification oligonucleotide that is SEQ ID No. 38, its complement and/or RNA equivalent and one or more second amplification oligonucleotides comprising sequences selected from the group consisting of SEQ ID Nos. 42, 19, 21, 23, 25, 27, complements thereof and/or RNA equivalents thereof, wherein at least one of the amplification oligonucleotides may include a 5′

promoter sequence that is non-complementary to an HPV target sequence.

2. The combination of oligonucleotides of claim 1, in which one or more individual oligonucleotides include a backbone that includes at least one 2′

-methoxy RNA group, at least one 2′

fluoro-substituted RNA group, at least one peptide nucleic acid linkage, at least one phosphorothioate linkage, at least one methylphosphonate linkage or any combination thereof.

3. The combination of oligonucleotides of claim 1, further comprising at least two capture oligonucleotides selected from the group consisting of SEQ ID Nos. 2, and 4, wherein each capture oligonucleotide may be joined to a ligand moiety.

4. The combination of oligonucleotides of claim 3, wherein at least one capture oligonucleotide comprises at least one 2′

-methoxy RNA group, at least one 2′

fluoro-substituted RNA group, at least one peptide nucleic acid linkage, at least one phosphorothioate linkage, or at least one methylphosphonate linkage.

5. A method of detecting the presence of human papillomavirus (HPV) nucleic acid present in a biological sample, comprising the steps of:

contacting nucleic acid in a biological sample suspected of containing RNA of at least one of HPV types 33 and 58 with a combination of amplification oligonucleotides that specifically hybridize to and amplify a HPV target sequence in an E7 target region sequence, wherein said combination of amplification oligonucleotides includes as a first amplification oligonucleotide at least one of;

SEQ ID NO;

24, 26, 25 joined at its 5′

end to a promoter sequences that is non-complementary to an HPV target sequence, and 27 joined at its 5′

end to a promoter sequences that is non-complementary to an HPV target sequence combined with a second amplification oligonucleotide that is with an amplification oligomer having a nucleotide sequence that is SEQ ID NO;

38;

amplifying a HPV target sequence from the target region sequence in at least one of HPV types 33 and 58 by using the amplification oligonucleotides and a nucleic acid polymerase in vitro to produce an HPV amplified product; and

detecting the amplified product to indicate the presence in the sample of at least one of HPV types 33 and 58 present in the biological sample.

6. The method of claim 5, further comprising a step before the amplifying step of separating RNA of at least one of HPV 33 and 58 from other components in the biological sample by contacting HPV RNA in the biological sample with a capture oligonucleotide that hybridizes to the HPV RNA and separating a complex that includes the capture oligonucleotide and HPV RNA from other components in the biological sample.

7. The method of claim 6, wherein the step of separating RNA of at least one HPV type uses a capture oligonucleotide that may be joined to a ligand moiety wherein said capture oligonucleotide has a target hybridizing sequence consisting essentially of SEQ ID NO:

4.

8. The method of claim 7, wherein the ligand moiety joined to the capture oligonucleotide is a nucleic acid that is non-complementary to an HPV sequence.

9. The method of claim 5, wherein the amplifying step uses an amplification process that is substantially isothermal.

10. The method of claim 6, wherein the amplifying step uses a transcription-associated amplification method.

11. The method of claim 5, wherein the detecting step uses a combination of probe oligonucleotides and at least one probe oligonucleotide bound to the HPV amplified product results in a signal that indicates the presence of at least one of HPV types 33 and 58 in the biological sample.

12. The method of claim 11, wherein the detecting step uses a consisting essentially of SEQ ID NO:

12 joined directly or indirectly to a label.

13. The method of claim 5, wherein the contacting step further includes introducing a non-HPV internal control sequence into the sample, wherein the amplifying step further includes amplifying the non-HPV internal control sequence to produce an amplified internal control sequence, and wherein the detecting step further includes detecting the amplified internal control sequence to produce a signal that indicates that the method steps have been performed appropriately.

14. The method of claim 5, further comprising performing a second reaction that includes the steps of:

contacting nucleic acid in the biological sample with a mixture of amplification oligonucleotides that amplify a HPV 16 target sequence or a HPV 18 target sequence, wherein both the HPV 16 target sequence and the HPV 18 target sequence are in an E6/E7 target region sequence;

amplifying the HPV 16 target sequence or the HPV 18 target sequence that is present in the sample by using the mixture of amplification oligonucleotides and a nucleic acid polymerase in vitro to produce an HPV 16 amplified product or an HPV 18 amplified product, depending on which HPV type or types are present in the sample; and

detecting the HPV 16 amplified product or the HPV 18 amplified product, depending on which HPV type or types are present in the sample, by using a detection probe specific for the HPV 16 amplified product or a detection probe specific for the HPV 18 amplified product, thereby detecting the presence of HPV 16 or HPV 18 in the sample.

15. The method of claim 14, wherein the second reaction uses:

in the amplifying step, a mixture of amplification oligonucleotides consisting of SEQ ID Nos. 18, 28, and 39 or a mixture of amplification oligonucleotides consists of SEQ ID Nos. 19, 29, and 39, and

in the detecting step, detection probes consisting of at least SEQ ID NO;

11 or SEQ ID NO;

45, sequences that are completely complementary to at least SEQ ID NO;

11 or SEQ ID NO;

45, RNA equivalents of at least SEQ ID NO;

11 or SEQ ID NO;

45, or RNA equivalents of the sequences completely complementary to at least SEQ ID NO;

11 or SEQ ID NO;

45, wherein each detection probe may be joined directly or indirectly to a label.

16. The method of claim 5, wherein said contacting step further comprises contacting said sample with amplification oligomers for amplifying a target sequence in one or more of HPV types 16, 18, 31, 35, 39, 45, 51, 52, 56, 59 and 68, providing conditions for amplifying and detecting amplified product therefrom.

17. The method of claim 16, wherein at least two of said HPV target sequences are amplified in a multiplex amplification reaction.

18. The method of claim 16, wherein said detecting step is performed using a labeled oligonucleotide probe.

19. The method of claim 18, wherein said labeled oligonucleotide probe is an AE labeled probe.